Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Evaluation of TNF-alpha Antagonists (Infliximab) Withdrawal in Sarcoidosis — Stella

Recruiting

Back to Sarcoidosis trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

France

Hôpital de la Pitié-Salpêtrière, Paris

Key details

Phase

Large-scale testing

Sponsor

Assistance Publique - Hôpitaux de Paris

Enrollment target

~90 participants

Started

March 2023

Primary completion

March 2026

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years and older

Last updated February 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov